PMH10 COST-EFFECTIVINESS ANALYSIS OF LONG ACTING MICROSPHERES OF RISPERIDONE (RISPERDAL CONSTA) IN THE TREATMENT OF SCHIZOPHRENIA IN MEXICO  by Vazquez, V
A74 Abstracts
effects associated with VPA and DVPX-ER estimated by the
expert panel was 0.36 and 0.10 respectively. The average prob-
ability of treatment success for VPA and DVPX-ER was esti-
mated to be 0.45 and 0.58 respectively. In the base case analysis,
the expected total cost per patient was $33,525 and $24,968 for
VPA and DVPX-ER respectively, a difference of $8557 favoring
ER. The expert panel also estimated the frequency of drug
switching within one year for VPA and DVPX-ER to be 58.3%
and 28.7% for VPA and DVPX-ER respectively. Finally, sensi-
tivity analysis results indicated DVPX-ER was the preferred
option when the probability of disease control with VPA was 0.5
or less, across all GI event probabilities with VPA. CONCLU-
SION: The results from our decision analysis, based on proba-
bilities of major events and associated utilization from an expert
panel, suggest that divalproex sodium extended-release provides
greater net beneﬁt than valproic acid in the treatment of bipolar
disorder.
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OBJECTIVES: The aim of the study was to estimate the cost-
effectiveness relation of the long-acting injection formulation of
Risperidone (LARI) IM every 2 weeks vs oral antipsychotics
Olanzapine and Risperidone and the traditional prolonged-
action antipsychotic injection formulation of haloperidol depot
in the pharmacological management of schizophrenia in Mexico.
Consequently, a pharmacoeconomic study was proposed using a
cost-effectiveness model in adult patients treated in the Mexican
Social Security Institute (IMSS). METHODS: A decision analy-
sis was developed using a retrospective and comparative cost-
effectiveness model over a 24 month period. A sample of
Schizophrenic patients was obtained using IMSS databases and
a decision tree based on relapses, hospitalization, pharmacolog-
ical treatment, hospital discharges and re-hospitalizations. To
determine the criteria for the effectiveness of each alternative, a
meta-analysis was carried out based on national and interna-
tional literature taking the clinical outcomes: total PANSS,
changes in body weight, AE, adherence, hospitalization, re-hos-
pitalization and relapses. The factors for costs were: speciﬁc
pharmacological therapy, outpatient consultations for treatment,
basal hospitalization, re-hospitalization, length of hospital stay
and absence from work. The decision tree was validated by a
panel of experts. RESULTS: Risperidone LA was the alternative
with the lowest cost for annual treatment ($84,877 pesos). Dif-
ferences versus the other treatment therapies were found in
regards to hospitalization, subsequent hospitalizations and, to a
lesser degree, absenteeism from work. Treatment with LARI pro-
duced savings of $8324 pesos compared to Haloperidol Depot
(the most widely used injected antipsychotic in Mexico); com-
pared to the second generation antipsychotics (atypical), savings
were $27,733 pesos versus Olanzapine and $1875 pesos versus
oral Risperidone. LARI produced the lowest number of re-hos-
pitalized patients and events requiring re-hospitalization as well
as superior clinical improvements compared to the other thera-
pies. CONCLUSION: The study demonstrated that LARI is a
cost-efﬁcient and dominant alternative for the treatment of schiz-
ophrenia patients in Mexico.
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OBJECTIVES: The objective of this study was to determine the
medication use patterns and costs associated with atypical
antipsychotics in the treatment of bipolar disorder. METHODS:
Data for this retrospective study were obtained from private
payer administrative claims. Bipolar patients were identiﬁed
based on one inpatient or two outpatient diagnoses of bipolar
disorder. Those who initiated on olanzapine, risperidone, queti-
apine, or ziprasidone during 2003, had not used the initiated
medication during the prior three-months, and met eligibility cri-
teria in prior six-months and post one-year were included.
RESULTS: Among the 1516 bipolar patients in this study, olan-
zapine (N = 507) was more likely to be initiated as the primary
bipolar medication (50.9%) than risperidone (39.9%, N = 424),
quetiapine (36.1%, N = 463) or ziprasidone (25.4%, N = 122).
During the post one-year, olanzapine was used as the only
primary bipolar medication for more days (73.5) than risperi-
done (53.7), quetiapine (56.3), and ziprasidone (36.6). Overall,
olanzapine and risperidone initiated patients incurred lower total
annual costs ($15,208 & $14,216 respectively) than quetiapine
($18,087)and ziprasidone ($18,729) initiated patients. CON-
CLUSION: Among the atypical antipsychotics studied, olanzap-
ine was used more often as a primary bipolar medication while
quetiapine and ziprasidone were used more in conjunction with
other bipolar medication for bipolar disorder.
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OBJECTIVES: To compare resource utilization in depressed
patients with and without co-morbid musculoskeletal chronic
pain (MSCP) and headache. METHODS: Caremark administra-
tive pharmacy and medical claims data were analyzed in this
study over a one-year period. ICD9 CM codes were used to iden-
tify participants with depression, MSCP and headache. Out-
comes included number of visits and expenditures associated
with ofﬁce visits (MD), emergency room visits (ER), hospital-
izations (HOS) using medical claims data, and prescription costs
(Rx) using pharmacy claims data. Logistic regression was used
to identify the demographic predictors of co-morbid MSCP and
headache in patients with depression. Analysis of covariance was
used to determine differences in health care use and expendi-
tures, adjusting for age, sex, and marital status. RESULTS: One-
year prevalence of MSCP and headache in depressed patients was
18%. Women with depression were 1.7 times more likely to have
MSCP or headache than men with depression (p < 0.0001). After
adjusting for age, sex and marital status, depressed patients with
MSCP and headache had signiﬁcantly more ER visits per year
(2.5 vs. 1.6, p < 0.0001) and physician visits per year (10.0 vs.
7.0, P < 0.0001). Annual ER, MD and Rx expenditures were sig-
niﬁcantly higher in the depression group with co-morbid MSCP
and headache (ER: $2008 vs. $1635, p < 0.0001 and MD: $559
vs. $412, p < 0.00001 and Rx: $3926 vs. $3111, p < 0.0001).
CONCLUSION: Depressed patients with co-morbid MSCP and
headache utilize more health care resources and incur higher
health care expenditures. Treating depression and pain in com-
bination could improve ﬁnancial and clinical outcomes.
